Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system

  title={Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system},
  author={Carmelo Erio Fiore and Stefania Riccobene and Roberto Antonio Mangiafico and Ferrucio Santoro and Pietra Pennisi},
  journal={Osteoporosis International},
We report a new case of hepatitis C-associated osteosclerosis (HCAO). The clinical presentation of the patient was an acquired deep severe bone pain with increased serum bone alkaline phosphatase activity (up to 12 times the upper limit of normal), and generalized bone sclerosis, temporally related to the hepatitis C-virus (HCV) infection. We documented in this patient an increase of circulating osteoprotegerin (OPG), and a concentration of circulating receptor activator for nuclear factor-kB… 
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
The case of a 59-year-old man with generalized bone pain and diagnosis of HCV infection, sequentially treated with cholecalciferol, prednisone, sofosbuvir associated with daclatasvir and ibandronate is reported.
Hepatitis C-associated osteosclerosis: a new case with long-term follow-up and a review of the literature.
The case of a 61-year-old woman affected by severe pain involving the lower limbs is described and a normalized radioisotope uptake on bone scanning 10 years after the diagnosis of hepatitis C-associated osteosclerosis is discussed.
An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis
Clinical presentation and imaging results of the 19th case of Hepatitis C-associated osteosclerosis are reported, finding that the etio-pathogenesis remains obscure but may bear important lessons in bone biology that could lead to new treatment options for osteoporosis.
A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin
Hepatitis C-associated osteosclerosis was improved by the combination therapy of peginterferon alfa-2b and ribavirin when the patient achieved sustained virological response.
A case of hepatitis C-associated osteosclerosis with xanthogranulomatous cholecystitis.
A 62-year-old woman presented with a markedly increased serum ALP level of skeletal origin during a regular follow-up of chronic hepatitis C and histopathological findings demonstrated xanthogranulomatous cholecystitis, which may indicate the existence of a novel osteogenic factor in the gallbladder in HCAO.
A case of hepatitis C-associated osteosclerosis in an elderly Japanese man.
An elderly Japanese man with HCAO, whose clinical course the authors followed for 3 years, and previous reports suggest that the skeletal tissue of this disease appears to be of good quality.
Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia
The main rheumatic symptoms that can occur during MC (HCV chronic infection) are reviewed and the principles underlying their clinical management are discussed.
Terpos Osteoporosis and osteosclerosis in sickle cell / β-thalassemia : the role of the RANKL / osteoprotegerin axis
Evaluated the bone mineral density (BMD) of HbS/β-thalassemia patients in parallel with markers of bone remodeling in an attempt to better understand the pathophysiology of bone disease in these patients.
Serum Sclerostin in Hepatitis C Virus Infected Patients
Serum sclerostin levels were within the normal range in HCV patients, and correlated directly with BMD and serum telopeptide, and the role of bones for intermediary metabolisms was suggested.


Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman.
It is found that bone mass can be restored by this disorder in a postmenopausal woman and understanding and control of the mechanism of HC-associated osteosclerosis could potentially lead to correction of low bone mass from osteoporosis with good quality skeletal tissue.
Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis.
It is demonstrated that HCAO patients have a specific increase in circulating big IGF-II (IGf-IIE) and IGF-binding protein-2 (IGFBP-2) levels, and that IGF- IIE and IGF BP-2 circulate together in a bioavailable, 50-kDa complex.
Painful diffuse osteosclerosis after intravenous drug abuse.
Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.
IGBP-2 may facilitate the targeting of IGFs, and in particular IGF-IIE, to skeletal tissue in HCAO patients, with a subsequent stimulation by IGFs of osteoblast function, suggesting a possible means to increase bone mass in patients with osteoporosis.
Doubling skeletal mass during adult life: The syndrome of diffuse osteosclerosis after intravenous drug abuse
  • M. Whyte, S. Teitelbaum, W. Reinus
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1996
It is shown that skeletal mass can be markedly increased with histologically normal, structurally sound bone during adult life and elucidation of the etiology and pathogenesis could offer an effective treatment for osteoporosis.
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis.
Creatine kinase brain isoenzyme (BB‐CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders
ABSTRACT: Absence of serum BB‐CK in adult type I disease suggests that this condition may not be a genuine form of OP, and quantitated total CK activity and CK isoenzymes in 15 patients representing the five major clinical forms of OP and in 22 patients representing 14 other types of sclerosing bone disease.
Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon.
Intrahepatic c-fos and c-myb were detected in chronic viral hepatitis patients, but not in non-viral liver diseases, and their expression correlated with the grade and stage of liver disease and with poor response to alpha-IFN.
Minireview: the OPG/RANKL/RANK system.
The identification of the OPG-ligand/osteoclast differentiating factor and subsequently RANKL, was identified as the key mediator of osteoclastogenesis in both a membrane-bound form expressed on preosteoblastic/stromal cells as well as a soluble form.